The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
ARDS - Acute lung injury
Publications
Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.
World journal of surgical oncology. 2017;15(1):49
Intravesical mitomycin-C-induced interstitial pneumonia.
Respiration; international review of thoracic diseases. 2010;80(3):256-9
Mitomycin lung toxicity. Acute and chronic phases.
American journal of clinical oncology. 1997;20(3):282-4
Pulmonary toxicity of mitomycin.
Cancer. 1980;45(2):236-44
Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic carcinoma. Severe pulmonary toxicity from q 3 weekly mitomycin C.
American journal of clinical oncology. 1984;7(6):719-24
Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma.
Archives of internal medicine. 1985;145(10):1905-7
A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma.
Cancer. 1986;58(7):1428-36
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
Cancer. 1979;43(5):1598-603